

Emmanuel Cognat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4081618/publications.pdf>

Version: 2024-02-01

51
papers

1,149
citations

623734

14
h-index

414414

32
g-index

58
all docs

58
docs citations

58
times ranked

1553
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. EBioMedicine, 2022, 75, 103793.	6.1	4
2	Telemedicine in French Memory Clinics During the COVID-19 Pandemic. Journal of Alzheimer's Disease, 2022, 86, 525-530.	2.6	3
3	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. Neurology, 2022, 99, .	1.1	8
4	A temporal classification method based on behavior time series data in patients with behavioral variant of frontotemporal dementia and apathy. Journal of Neuroscience Methods, 2022, 376, 109625.	2.5	0
5	Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive Impairment. Alcoholism: Clinical and Experimental Research, 2021, 45, 561-565.	2.4	8
6	Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review. Diagnostics, 2021, 11, 754.	2.6	7
7	Preventing Post-Lumbar Puncture Headache. Annals of Emergency Medicine, 2021, 78, 443-450.	0.6	14
8	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurology, 2021, 78, 1471.	9.0	204
9	Characteristics of Bipolar Patients with Cognitive Impairment of Suspected Neurodegenerative Origin: A Multicenter Cohort. Journal of Personalized Medicine, 2021, 11, 1183.	2.5	5
10	Contribution of cerebrospinal fluid Alzheimer biomarkers to the diagnosis of Creutzfeldt-Jakob disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
11	Reduction of behavioural inhibition disorders in behavioural variant frontotemporal dementia patients observed under semi-ecological conditions. Alzheimer's and Dementia, 2021, 17, .	0.8	0
12	Grey and white matter correlates of behavioural disinhibition assessed under semi-ecological conditions in behavioural variant frontotemporal dementia.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e053669.	0.8	0
13	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. PLoS Medicine, 2020, 17, e1003289.	8.4	39
14	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037097.	0.8	0
15	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 74, 903-911.	2.6	9
16	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. Neurology, 2020, 95, e953-e961.	1.1	50
17	Title is missing!. , 2020, 17, e1003289.		0
18	Title is missing!. , 2020, 17, e1003289.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 17, e1003289.		0
20	Title is missing!. , 2020, 17, e1003289.		0
21	Title is missing!. , 2020, 17, e1003289.		0
22	Title is missing!. , 2020, 17, e1003289.		0
23	Title is missing!. , 2020, 17, e1003289.		0
24	Intracranial Extension of Extracranial Vertebral Dissection Is Associated With an Increased Risk of Ischemic Events. Stroke, 2019, 50, 2231-2233.	2.0	10
25	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. BMJ Open, 2019, 9, e026380.	1.9	17
26	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β -amyloid peptide and tau. PLoS ONE, 2019, 14, e0217026.	2.5	18
27	CSF level of β -amyloid peptide predicts mortality in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 29.	6.2	19
28	O2â€05â€01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P545.	0.8	2
29	CSF synaptic proteins and plasmatic NFL correlate with cognitive function but reflect different brain lesions: A biomarker study. Morphologie, 2019, 103, 87.	0.9	0
30	Endovascular management of extracranial occlusions at the hyperacute phase of stroke with tandem occlusions. Journal of Neuroradiology, 2018, 45, 196-201.	1.1	13
31	Elevated ALS Biomarker Levels in CSF of a FTD Patient at the Presymptomatic Stage of ALS. Alzheimer Disease and Associated Disorders, 2018, 32, 156-157.	1.3	3
32	O3â€14â€06: DISSECTION OF SYNAPTIC PATHWAYS THROUGH THE ANALYSIS OF BIOMARKERS IN THE CSF: A COMBINING TOOL FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1061.	0.8	0
33	P3â€249: COMBINING MATHEMATICAL MODEL AND CATECHOLAMINE QUANTIFICATIONS TO SCREEN ALZHEIMER DISEASE FROM A SIMPLE BLOOD TEST. Alzheimer's and Dementia, 2018, 14, P1168.	0.8	0
34	Blood-Based Kinase Assessments in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 338.	3.4	11
35	Increased PKR level in human CADASIL brains. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 771-774.	2.8	1
36	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders. Journal of Alzheimer's Disease, 2018, 64, 889-897.	2.6	9

#	ARTICLE	IF	CITATIONS
37	Visibility of blood flow on optical coherence tomography angiography in a case of branch retinal artery occlusion. <i>Journal of Ophthalmic and Vision Research</i> , 2018, 13, 75.	1.0	5
38	Biomarqueurs du liquide c�r�brospinal dans la maladie d'Alzheimer. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 307-320.	0.0	1
39	Differential diagnosis between sarcoidosis and granulomatosis with polyangiitis in a patient with leptomenigeal, cavernous sinus and pituitary lesions. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017, 110, 691-692.	0.5	3
40	[P1�240]: CLINICAL IMPACT OF CEREBROSPINAL FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT DIAGNOSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P336.	0.8	1
41	OUP accepted manuscript. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017, 110, 397-398.	0.5	4
42	Reducing α 3 or vitronectin ameliorates disease manifestations in <i>CADASIL</i> mice. <i>Annals of Neurology</i> , 2016, 79, 387-403.	5.3	74
43	Potassium channelopathy-like defect underlies early-stage cerebrovascular dysfunction in a genetic model of small vessel disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E796-805.	7.1	77
44	<i>CADASIL</i> and <i>CARASIL</i> . <i>Brain Pathology</i> , 2014, 24, 525-544.	4.1	155
45	Response to Letter Regarding Article, "Archetypal Arg169Cys Mutation in NOTCH3 Does Not Drive the Pathogenesis in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leucoencephalopathy via a Loss-of-Function Mechanism". <i>Stroke</i> , 2014, 45, e129.	2.0	2
46	Archetypal Arg169Cys Mutation in NOTCH3 Does Not Drive the Pathogenesis in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leucoencephalopathy via a Loss-of-Function Mechanism. <i>Stroke</i> , 2014, 45, 842-849.	2.0	34
47	Early white matter changes in <i>CADASIL</i> : evidence of segmental intramyelinic oedema in a pre-clinical mouse model. <i>Acta Neuropathologica Communications</i> , 2014, 2, 49.	5.2	45
48	Abnormal recruitment of extracellular matrix proteins by excess Notch3ECD: a new pathomechanism in <i>CADASIL</i> . <i>Brain</i> , 2013, 136, 1830-1845.	7.6	167
49	Transcranial magnetic stimulation as an efficient treatment for psychogenic movement disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1043-1046.	1.9	61
50	Cerebral Venous Thrombosis in Inflammatory Bowel Diseases: Eight Cases and Literature Review. <i>International Journal of Stroke</i> , 2011, 6, 487-492.	5.9	53
51	"Habit" gambling behaviour caused by ischemic lesions affecting the cognitive territories of the basal ganglia. <i>Journal of Neurology</i> , 2010, 257, 1628-1632.	3.6	6